Essential Oil Regulations in the USA: FDA, FTC, and Labeling

Essential oils occupy one of the most ambiguous regulatory categories in the United States. The same bottle of lavender oil can be a cosmetic, a drug, a household product, or a food additive depending on its intended use and the claims printed on the label. For US brands sourcing essential oils from China, misunderstanding these distinctions can mean FDA warning letters, FTC enforcement, or product seizures. This guide clarifies the framework.

How the FDA Classifies Essential Oils

The FDA does not regulate “essential oils” as a category. Instead, classification depends on intended use, which the agency determines from labeling, marketing, and consumer perception.

Cosmetic

An essential oil marketed for cleansing, beautifying, or altering appearance is a cosmetic under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Examples include lavender oil sold as a skin toner, tea tree oil sold for blemish care, or rose oil sold as a perfume ingredient.

Cosmetics do not require FDA pre-approval, but they must:

• Comply with 21 CFR Part 701 labeling requirements
• Be manufactured under Good Manufacturing Practices (now codified under the Modernization of Cosmetics Regulation Act of 2022, MoCRA)
• Be registered with the FDA under MoCRA’s facility and product listing requirements (effective 2024)
• Avoid adulterated or misbranded status

Drug

An essential oil marketed to diagnose, treat, cure, or prevent disease, or to affect the structure or function of the body, is a drug. Claims that trigger drug classification include:

• “Treats anxiety” or “relieves depression”
• “Cures insomnia”
• “Reduces inflammation”
• “Antifungal” or “antibacterial” (when applied to the body)
• “Boosts immune system”

Drugs require an NDA (New Drug Application) or compliance with an OTC monograph, a process costing millions of dollars and taking years. Most essential oil brands cannot legally make these claims.

Food Additive or Dietary Supplement

Essential oils sold for ingestion are either food additives (requiring GRAS status or pre-market approval) or dietary supplements (regulated under DSHEA with separate labeling rules under 21 CFR Part 101). Few essential oils have GRAS affirmation for direct consumption, and ingestion marketing carries significant liability.

Household Product

Essential oils marketed purely for aromatherapy ambiance, diffusion, or household scenting without body-application or therapeutic claims fall outside FDA jurisdiction and are treated as consumer products under CPSC oversight.

FTC Advertising Rules

The Federal Trade Commission regulates advertising claims under Section 5 of the FTC Act, requiring that all objective claims be substantiated by competent and reliable scientific evidence. The FTC has issued warning letters and settlements against essential oil companies for:

• Disease-treatment claims without clinical evidence
• Misleading “100 percent pure” or “therapeutic grade” claims (note: “therapeutic grade” is a marketing term with no regulatory definition)
• False country-of-origin or organic claims

Penalties can reach USD 50,000 per violation per day under FTC civil penalty authority.

Labeling Requirements by Category

Cosmetic Essential Oil Label (21 CFR 701)

• Principal Display Panel: product identity, net quantity (metric and imperial)
• Information Panel:
  • Full ingredient list using INCI names in descending order of predominance
  • Name and address of manufacturer, packer, or distributor
  • Country of origin (e.g., “Made in China” or “Product of China”)
  • Warning statements where required (e.g., “For external use only”)
  • Directions for safe use
• No drug claims anywhere on the label or accompanying materials

Household / Aromatherapy Label (CPSC / FHSA)

• Product identity
• Net contents
• Manufacturer or importer name and address
• Country of origin
• Hazard warnings per FHSA where applicable (e.g., “May cause skin sensitization,” “Keep away from children”)
• ASTM-compliant warnings for any candle or flame-related format

Dietary Supplement Label (21 CFR 101, if applicable)

• “Supplement Facts” panel
• Full ingredient disclosure
• “This statement has not been evaluated by the FDA” disclaimer for any structure-function claim
• Manufacturer contact for adverse event reporting

MoCRA: The New Cosmetic Compliance Baseline

The Modernization of Cosmetics Regulation Act of 2022 introduced the most significant FDA cosmetic reform in 80 years. Effective requirements include:

• Facility registration with the FDA (initial deadline December 29, 2023, biennial renewal)
• Product listing with full ingredient information
• Adverse event reporting within 15 business days of a serious event
• GMP compliance per FDA-issued regulations (finalized 2024)
• Mandatory recall authority for the FDA

US brands importing essential oil cosmetics from China must ensure their Chinese manufacturer is registered, the product is listed, and adverse event reporting flows back through the supply chain.

Common Compliance Mistakes

1. Mixing cosmetic and drug claims on the same label (“moisturizes skin and treats eczema”).
2. Using “therapeutic grade” as if it were a regulated standard.
3. Omitting INCI ingredient names in favor of common names only.
4. Failing to register the Chinese facility under MoCRA.
5. Marketing ingestion of oils not affirmed as GRAS.
6. Missing Prop 65 evaluation for California sales (relevant for constituents such as safrole, methyleugenol, and estragole).

Working with a Chinese Essential Oil Supplier

A compliant supplier should provide:

• GC-MS chromatogram for every batch
• Country-of-origin documentation for botanical source
• IFRA certificate for any blend sold as fragrance
• SDS in GHS format
• MoCRA facility registration confirmation (for cosmetic-grade oils)
• Allergen disclosure per EU CLP and IFRA, which US premium retailers increasingly request
• Heavy metal and pesticide testing for any oil intended for topical use

At Aromiso, essential oil and fragrance oil shipments to the US include batch-specific GC-MS data, IFRA documentation, and a written claim-review note flagging any marketing language that could trigger FDA drug classification.

Cost of Compliance

For a US brand launching a 6-SKU essential oil line:

• FDA facility registration: USD 0 (no fee), but USD 1,000 to USD 3,000 in consulting
• Product listing: USD 0 fee, internal time
• INCI label review: USD 300 to USD 800 per SKU
• GC-MS testing per batch: USD 150 to USD 400
• Prop 65 screening: USD 500 to USD 1,500 per SKU
• Legal review of marketing claims: USD 1,500 to USD 5,000

Total first-year compliance budget: roughly USD 5,000 to USD 15,000, modest against the cost of an FDA warning letter or FTC investigation.

Final Thoughts

Essential oil regulation in the USA is determined by claims, not by the product itself. US brands that succeed keep their marketing language disciplined, register their Chinese manufacturing partners under MoCRA, and treat labeling as a legal document rather than a design canvas. The brands that get into trouble are almost always the ones that promised too much on the label.